HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BHST

BioHarvest Sciences Inc. Common Stock (NASDAQ)

Consumer Defensive — Packaged Foods

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.

None 4 analysts
$2.18
$-0.10 (-4.39%)
Target: $12.75 (484.9%)
Sign in to add BHST to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$65.96M
P/E Ratio (TTM)-
Forward P/E-17.64
EPS (TTM)$-0.58
Dividend Yield-
Profit Margin-32.54%
Revenue Growth8.20%
ROE-103.29%
Debt/Equity60.98
Recommendation None
Analyst Target$12.75
Analysts4
Indexes NASDAQ

Technical Indicators

RSI (14)42.4
Beta1.35
SMA 20-
SMA 40-
52-Week High$12.80
52-Week Low$2.75
50-Day Avg$3.67
200-Day Avg$5.78
Avg Volume33.5K
Volume94.3K

Performance Analysis

NEUTRAL

BHST presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($2.75), which could present a value opportunity.
~ RSI at 42.4 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 8.2% year-over-year.
- Operating at a loss with -32.5% margin.
~ Wall Street consensus is "none" from 4 analysts.
+ Average analyst target of $12.75 implies 484.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 12:59 UTC

Back to Screener Export Report